202 related articles for article (PubMed ID: 11289162)
61. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers.
Zhang X; Sun Q; Shan M; Niu M; Liu T; Xia B; Liang X; Wei W; Sun S; Zhang Y; Liu XS; Song Q; Yang Y; Ma Y; Liu Y; Yang L; Ren Y; Zhang G; Pang D
PLoS One; 2013; 8(1):e53931. PubMed ID: 23349767
[TBL] [Abstract][Full Text] [Related]
62. [Heterogeneous expression of cyclin D3 in breast carcinoma:absence of prognostic significance in a series of 92 cases with long follow-up].
Doglioni C; Mauri FA; Ferrero S; Russo AG; Midolo de Luca V; Caffo O; Galligioni E; Dalla Palma P; Barbareschi M
Pathologica; 1999 Oct; 91(5):410-1. PubMed ID: 10777967
[No Abstract] [Full Text] [Related]
63. Loss of expression of cyclin d2 by aberrant DNA methylation: a potential biomarker in vietnamese breast cancer patients.
Truong PK; Lao TD; Doan TP; Le TA
Asian Pac J Cancer Prev; 2015; 16(6):2209-13. PubMed ID: 25824739
[TBL] [Abstract][Full Text] [Related]
64. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.
Miyamoto K; Fukutomi T; Asada K; Wakazono K; Tsuda H; Asahara T; Sugimura T; Ushijima T
Jpn J Clin Oncol; 2002 Mar; 32(3):79-84. PubMed ID: 11956301
[TBL] [Abstract][Full Text] [Related]
65. Molecular analysis of premalignant and carcinoma in situ lesions of the human breast.
Steeg PS; Clare SE; Lawrence JA; Zhou Q
Am J Pathol; 1996 Sep; 149(3):733-8. PubMed ID: 8780376
[No Abstract] [Full Text] [Related]
66. Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors.
Li Z; Chen B; Wu Y; Jin F; Xia Y; Liu X
BMC Cancer; 2010 Mar; 10():98. PubMed ID: 20230646
[TBL] [Abstract][Full Text] [Related]
67. Hypermethylation of CCND2 in Lung and Breast Cancer Is a Potential Biomarker and Drug Target.
Hung CS; Wang SC; Yen YT; Lee TH; Wen WC; Lin RK
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30308939
[TBL] [Abstract][Full Text] [Related]
68. Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma.
Alanen K; Deng DX; Chakrabarti S
Histopathology; 2000 Feb; 36(2):161-7. PubMed ID: 10672062
[TBL] [Abstract][Full Text] [Related]
69. [Promoter methylation and mRNA expression of MCF10 model cell lines of breast cancer].
Yang JL; Klinkebiel D; Boland MJ; Tang L; Christman JK
Zhonghua Bing Li Xue Za Zhi; 2005 Mar; 34(3):177-8. PubMed ID: 15938832
[No Abstract] [Full Text] [Related]
70. Induction and expression of cyclin D3 in human pancreatic cancer.
Ebert MP; Hernberg S; Fei G; Sokolowski A; Schulz HU; Lippert H; Malfertheiner P
J Cancer Res Clin Oncol; 2001 Jul; 127(7):449-54. PubMed ID: 11469683
[TBL] [Abstract][Full Text] [Related]
71. The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer.
Wang D; Li C; Zhang X
DNA Cell Biol; 2014 Sep; 33(9):581-90. PubMed ID: 24842653
[TBL] [Abstract][Full Text] [Related]
72. Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells.
Parker BS; Cutts SM; Nudelman A; Rephaeli A; Phillips DR; Sukumar S
Cancer Biol Ther; 2003; 2(3):259-63. PubMed ID: 12878861
[TBL] [Abstract][Full Text] [Related]
73. Epigenetic silencing of DSC3 is a common event in human breast cancer.
Oshiro MM; Kim CJ; Wozniak RJ; Junk DJ; Muñoz-Rodríguez JL; Burr JA; Fitzgerald M; Pawar SC; Cress AE; Domann FE; Futscher BW
Breast Cancer Res; 2005; 7(5):R669-80. PubMed ID: 16168112
[TBL] [Abstract][Full Text] [Related]
74. Low expression of cyclin D2 in G2/M-arrested and transformed proliferating Balb/3T3 cells.
Fang MZ; Lee MH; Lee YS; Kim YC; Lee BM; Cho MH
J Vet Med Sci; 2002 Mar; 64(3):201-5. PubMed ID: 11999438
[TBL] [Abstract][Full Text] [Related]
75. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung.
Mehrotra J; Vali M; McVeigh M; Kominsky SL; Fackler MJ; Lahti-Domenici J; Polyak K; Sacchi N; Garrett-Mayer E; Argani P; Sukumar S
Clin Cancer Res; 2004 May; 10(9):3104-9. PubMed ID: 15131050
[TBL] [Abstract][Full Text] [Related]
76. Characterization of cyclin D2 expression in human endometrium.
Choi D; Yoon S; Lee E; Hwang S; Song S; Kim J; Yoon BK; Lee JH
J Soc Gynecol Investig; 2002; 9(1):41-6. PubMed ID: 11839508
[TBL] [Abstract][Full Text] [Related]
77. LAF-4 is aberrantly expressed in human breast cancer.
To MD; Faseruk SA; Gokgoz N; Pinnaduwage D; Done SJ; Andrulis IL
Int J Cancer; 2005 Jul; 115(4):568-74. PubMed ID: 15704140
[TBL] [Abstract][Full Text] [Related]
78. The expression of pseudogene cyclin D2 mRNA in the human ovary may be a novel marker for decreased ovarian function associated with the aging process.
Choi D; Yoon S; Lee E; Hwang S; Yoon B; Lee J
J Assist Reprod Genet; 2001 Feb; 18(2):110-3. PubMed ID: 11285977
[TBL] [Abstract][Full Text] [Related]
79. WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type.
Ugolini F; Charafe-Jauffret E; Bardou VJ; Geneix J; Adélaïde J; Labat-Moleur F; Penault-Llorca F; Longy M; Jacquemier J; Birnbaum D; Pébusque MJ
Oncogene; 2001 Sep; 20(41):5810-7. PubMed ID: 11593386
[TBL] [Abstract][Full Text] [Related]
80. Significance of metallothionein expression in breast myoepithelial cells.
Jin R; Bay BH; Chow VT; Tan PH; Dheen T
Cell Tissue Res; 2001 Feb; 303(2):221-6. PubMed ID: 11291768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
